Recent advances in the discovery and delivery of vaccine adjuvants
Derek T O'Hagan, Nicholas M Valiante, Derek T O'Hagan, Nicholas M Valiante
Abstract
Adjuvant design has historically had a touch of alchemy at its heart due to its reliance on the complex biology of innate immune activation. However, a new mechanistic understanding of innate immunity, combined with new adjuvant and delivery platforms for exploiting this knowledge, has led to significant advances recently. Although many challenges remain, the field is moving rapidly and the proper tools and methodologies are in place for the use of traditional drug discovery engines in guiding the development of vaccine adjuvants. In this review, we outline the current trends in immune potentiator, delivery system and adjuvant design that will shape the vaccines of the future.
Figures
References
- WHO World Health Report (2002).
- Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm. Res. 2002;19:715–728. doi: 10.1023/A:1016104910582.
- Medzhitov R, Preston-Hurlburt P, Janeway CA., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397. doi: 10.1038/41131.
- Takeda K, Kaisho T, Akira S. Toll-like receptors. Ann. Rev. Immunol. 2003;21:335–376. doi: 10.1146/annurev.immunol.21.120601.141126.
- Medzhitov R, Janeway CA., Jr. An ancient system of host defense. Curr. Opin. Immunol. 1998;10:12–15. doi: 10.1016/S0952-7915(98)80024-1.
- O'Hagan, D. & Valiante, N. M. Recent advances in vaccine adjuvants and delivery systems. Pharmaceutical News (in the press).
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. doi: 10.1038/32588.
- Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 1997;9:10–16. doi: 10.1016/S0952-7915(97)80153-7.
- Banchereau J, et al. Immunobiology of dendritic cells. Ann. Rev. Immunol. 2000;18:767–811. doi: 10.1146/annurev.immunol.18.1.767.
- Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 1987;165:302–319. doi: 10.1084/jem.165.2.302.
- Bachmann MF, et al. The influence of antigen organization on B cell responsiveness. Science. 1993;262:1448–1451. doi: 10.1126/science.8248784.
- Jegerlehner A, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine. 2002;20:3104–3112. doi: 10.1016/S0264-410X(02)00266-9.
- Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002;298:2199–2202. doi: 10.1126/science.1076071.
- Liu N, Ohnishi N, Ni L, Akira S, Bacon KB. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nature Immunol. 2003;4:687–693. doi: 10.1038/ni941.
- Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by Dectin-1 and Toll-like receptor 2. J. Exp. Med. 2003;197:1107–1117. doi: 10.1084/jem.20021787.
- Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410:1103–1107. doi: 10.1038/35074114.
- Cella M, et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 1999;189:821–829. doi: 10.1084/jem.189.5.821.
- Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001;14:303–313. doi: 10.1016/S1074-7613(01)00111-X.
- Royle MC, Totemeyer S, Alldridge LC, Maskell DJ, Bryant CE. Stimulation of Toll-Like receptor 4 by lipopolysaccharide during cellular invasion by live Salmonella typhimurium is a critical but not exclusive event leading to macrophage responses. J. Immunol. 2003;170:5445–5454. doi: 10.4049/jimmunol.170.11.5445.
- Nau GJ, Schlesinger A, Richmond JF, Young RA. Cumulative toll-like receptor activation in human macrophages treated with whole bacteria. J. Immunol. 2003;170:5203–5209. doi: 10.4049/jimmunol.170.10.5203.
- Hemmi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 2002;3:196–200. doi: 10.1038/ni758.
- Jurk M, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nature Immunol. 2002;3:499. doi: 10.1038/ni0602-499.
- Vasilakos JP, et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 2000;204:64–74. doi: 10.1006/cimm.2000.1689.
- Vogel FR, Powell MF. Vaccine Design: The Subunit and Adjuvant Approach. 1995. pp. 141–228.
- Zinkernagel RM, et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 1997;156:199–209. doi: 10.1111/j.1600-065X.1997.tb00969.x.
- Edelman R. New Generation Vaccines. 1997. pp. 173–192.
- Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev. Vaccines. 2003;2:165–188.
- Ott G. Vaccine Adjuvants: Preparation Methods and Research Protocols. 2001. pp. 211–228.
- Dupuis M, et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 2001;31:2910–2918. doi: 10.1002/1521-4141(2001010)31:10<2910::AID-IMMU2910>;2-3.
- Peppoloni S, et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines. 2003;2:285–293. doi: 10.1586/14760584.2.2.285.
- Keefer MC, et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses. 1996;12:683–693. doi: 10.1089/aid.1996.12.683.
- Ott G. Vaccine Design: The Subunit and Adjuvant Approach. 1995. pp. 229–248.
- Johnson OL, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 1996;2:795–799. doi: 10.1038/nm0796-795.
- Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 1999;11:753–761. doi: 10.1016/S1074-7613(00)80149-1.
- O'Hagan D, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines. 2003;2:269–283. doi: 10.1586/14760584.2.2.269.
- Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 2002;19:73–98. doi: 10.1615/CritRevTherDrugCarrierSyst.v19.i1.20.
- Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control Release. 2000;67:347–356. doi: 10.1016/S0168-3659(00)00226-1.
- Otten GR, et al. Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles. J. Virol. 2003;77:6087–6092. doi: 10.1128/JVI.77.10.6087-6092.2003.
- Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA. 2000;97:811–816. doi: 10.1073/pnas.97.2.811.
- O'Hagan D, et al. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J. Virol. 2001;75:9037–9043. doi: 10.1128/JVI.75.19.9037-9043.2001.
- Denis-Mize KS, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 2000;7:2105–2112. doi: 10.1038/sj.gt.3301347.
- Singh M, et al. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res. 2001;18:1476–1479. doi: 10.1023/A:1012269226066.
- Michalek SM, O'Hagan D, Gould-Fogerite S. Mucosal Immunology. 1999. pp. 759–778.
- Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 1999;20:493–500. doi: 10.1016/S0167-5699(99)01523-6.
- Baudner BC, et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun. 2002;70:4785–4790. doi: 10.1128/IAI.70.9.4785-4790.2002.
- Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control Release. 2001;70:267–276. doi: 10.1016/S0168-3659(00)00330-8.
- Ugozzoli M, Mariani M, Del Giudice G, Soenawan E, O'Hagan DT. Combinations of protein polysaccharide conjugate vaccines for intranasal immunization. J. Infect. Dis. 2002;186:1358–1361. doi: 10.1086/344320.
- Barackman JD, Ott G, Pine S, O'Hagan DT. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol. 2001;8:652–657.
- O'Hagan D. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 1998;34:305–320. doi: 10.1016/S0169-409X(98)00045-3.
- Katz DE, et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine. 2003;21:341–346. doi: 10.1016/S0264-410X(02)00613-8.
- Canter J, et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch. Intern. Med. 1990;150:1923–1927. doi: 10.1001/archinte.1990.00390200105020.
- Jackson LA, et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine. 2001;19:4703–4709. doi: 10.1016/S0264-410X(01)00225-0.
- Chen D, et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nature Med. 2000;6:1187–1190. doi: 10.1038/80538.
- Parent du Chatelet I, et al. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group. Vaccine. 1997;15:449–458. doi: 10.1016/S0264-410X(96)00173-9.
- Epstein JE, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum. Gene Ther. 2002;13:1551–1560. doi: 10.1089/10430340260201644.
- Roy MJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 2000;19:764–778. doi: 10.1016/S0264-410X(00)00302-9.
- Mikszta JA, et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Med. 2002;8:415–419. doi: 10.1038/nm0402-415.
- Matriano JA, et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 2002;19:63–70. doi: 10.1023/A:1013607400040.
- Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature. 1998;391:851. doi: 10.1038/36014.
- Glenn GM, et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nature Med. 2000;6:1403–1406. doi: 10.1038/82225.
- Guerena-Burgueno F, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 2002;70:1874–1880. doi: 10.1128/IAI.70.4.1874-1880.2002.
- Scharton-Kersten T, et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 2000;68:5306–5313. doi: 10.1128/IAI.68.9.5306-5313.2000.
- Guebre-Xabier M, et al. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 2003;77:5218–5225. doi: 10.1128/JVI.77.9.5218-5225.2003.
- Dilraj A, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet. 2000;355:798–803. doi: 10.1016/S0140-6736(99)95140-1.
- Giuliani MM, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 1998;187:1123–1132. doi: 10.1084/jem.187.7.1123.
- Giannelli V, et al. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun. 1997;65:331–334.
Source: PubMed